All-In Summit Highlights, Schools Could Block Social Media, FTC Chatbot Investigation, and Zoox hits Vegas | E2177

What It Covers

This Week in Startups covers All-In Summit highlights featuring Elon Musk on Optimus robots, Alex Karp on Palantir's civil liberties protections, debates on Ukraine funding, social media school bans, and autonomous vehicle progress from Zoox and Tesla.

Key Questions Answered

• •Humanoid Robot Manufacturing: Elon Musk dedicates majority mental cycles to Optimus version three, which requires creating entire supply chain from scratch including custom actuators unavailable from existing suppliers. Tesla's factory expertise combined with computer vision from autonomous vehicles positions them uniquely to produce robots at scale for approximately one dollar per hour operating cost.
• •Data Privacy Architecture: Palantir's software includes immutable logs, access control lists, and serialization features that make civil liberties abuses extremely difficult. Every data query creates permanent audit trail with biometric authentication, making it impossible for users to secretly access information without triggering alarms and review processes by oversight personnel.
• •School Technology Policy: Representative Angie Craig proposes No Social Media at School Act requiring companies to geofence around school campuses, blocking student access during school hours. Physical phone lockers costing one hundred to two hundred dollars per unit provide immediate solution, similar to designated smoking areas from previous decades but addressing more harmful addiction.
• •Autonomous Vehicle Safety: Zoox purpose-built robotaxi features bidirectional driving capability eliminating need for U-turns, sliding doors on both sides for safer entry, and extensive airbag systems throughout cabin. Design prioritizes low-speed urban environments at thirty five miles per hour or below, with safety testing showing superior crash protection compared to traditional vehicles.
• •GLP-1 Weight Management: Forty pound weight loss achieved over two year period using GLP-1 medications like Ozempic, initially prescribed off-label for visceral fat reduction. Eli Lilly CEO Dave Ricks confirms ongoing discovery of additional health benefits beyond weight loss, with services like Roe.co providing FDA-approved access through licensed provider consultations.